BioCryst Pharmaceuticals, Inc. (BCRX)
USD 8.93
(2.53%)
USD 8.93
(2.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 331.41 Million USD | 22.37% |
| 2022 | 270.82 Million USD | 72.31% |
| 2021 | 157.17 Million USD | 782.38% |
| 2020 | 17.81 Million USD | -63.53% |
| 2019 | 48.83 Million USD | 136.45% |
| 2018 | 20.65 Million USD | -18.0% |
| 2017 | 25.18 Million USD | -4.43% |
| 2016 | 26.35 Million USD | -45.39% |
| 2015 | 48.25 Million USD | 254.62% |
| 2014 | 13.6 Million USD | -21.48% |
| 2013 | 17.33 Million USD | -34.09% |
| 2012 | 26.29 Million USD | 33.85% |
| 2011 | 19.64 Million USD | -69.07% |
| 2010 | 63.5 Million USD | -14.87% |
| 2009 | 74.58 Million USD | 31.87% |
| 2008 | 56.56 Million USD | -20.6% |
| 2007 | 71.23 Million USD | 1046.79% |
| 2006 | 6.21 Million USD | 3990.38% |
| 2005 | 151.86 Thousand USD | -54.92% |
| 2004 | 336.9 Thousand USD | -79.38% |
| 2003 | 1.63 Million USD | -7.92% |
| 2002 | 1.77 Million USD | -84.1% |
| 2001 | 11.15 Million USD | 236.52% |
| 2000 | 3.31 Million USD | 32.62% |
| 1999 | 2.5 Million USD | -60.94% |
| 1998 | 6.4 Million USD | 540.0% |
| 1997 | 1 Million USD | -62.96% |
| 1996 | 2.7 Million USD | 1250.0% |
| 1995 | 200 Thousand USD | -71.43% |
| 1994 | 700 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 92.76 Million USD | -0.69% |
| 2024 Q2 | 109.33 Million USD | 17.86% |
| 2024 Q3 | 117.08 Million USD | 7.09% |
| 2023 Q3 | 86.74 Million USD | 5.15% |
| 2023 Q1 | 68.77 Million USD | -13.54% |
| 2023 Q2 | 82.49 Million USD | 19.94% |
| 2023 FY | 331.41 Million USD | 22.37% |
| 2023 Q4 | 93.4 Million USD | 7.68% |
| 2022 FY | 270.82 Million USD | 72.31% |
| 2022 Q1 | 49.92 Million USD | 5.86% |
| 2022 Q2 | 65.53 Million USD | 31.27% |
| 2022 Q3 | 75.82 Million USD | 15.71% |
| 2022 Q4 | 79.54 Million USD | 4.9% |
| 2021 Q4 | 47.15 Million USD | 15.04% |
| 2021 FY | 157.17 Million USD | 782.38% |
| 2021 Q1 | 19.05 Million USD | 374.58% |
| 2021 Q2 | 49.95 Million USD | 162.13% |
| 2021 Q3 | 40.99 Million USD | -17.94% |
| 2020 FY | 17.81 Million USD | -63.53% |
| 2020 Q1 | 4.82 Million USD | -87.86% |
| 2020 Q2 | 2.87 Million USD | -40.47% |
| 2020 Q3 | 6.1 Million USD | 112.54% |
| 2020 Q4 | 4.01 Million USD | -34.19% |
| 2019 Q4 | 39.72 Million USD | 2138.03% |
| 2019 Q3 | 1.77 Million USD | 22.58% |
| 2019 Q1 | 5.88 Million USD | 115.72% |
| 2019 Q2 | 1.44 Million USD | -75.4% |
| 2019 FY | 48.83 Million USD | 136.45% |
| 2018 Q2 | 12.49 Million USD | 214.24% |
| 2018 FY | 20.65 Million USD | -18.0% |
| 2018 Q1 | 3.97 Million USD | 2.21% |
| 2018 Q3 | 1.45 Million USD | -88.36% |
| 2018 Q4 | 2.72 Million USD | 87.69% |
| 2017 Q3 | 8.76 Million USD | 182.67% |
| 2017 FY | 25.18 Million USD | -4.43% |
| 2017 Q1 | 9.43 Million USD | 5.05% |
| 2017 Q4 | 3.89 Million USD | -55.59% |
| 2017 Q2 | 3.09 Million USD | -67.16% |
| 2016 Q1 | 4.82 Million USD | 4.74% |
| 2016 Q4 | 8.98 Million USD | 15.72% |
| 2016 FY | 26.35 Million USD | -45.39% |
| 2016 Q3 | 7.76 Million USD | 62.17% |
| 2016 Q2 | 4.78 Million USD | -0.68% |
| 2015 Q4 | 4.6 Million USD | -58.11% |
| 2015 Q2 | 25.84 Million USD | 278.58% |
| 2015 Q1 | 6.82 Million USD | 25.34% |
| 2015 FY | 48.25 Million USD | 254.62% |
| 2015 Q3 | 10.98 Million USD | -57.48% |
| 2014 FY | 13.6 Million USD | -21.48% |
| 2014 Q4 | 5.44 Million USD | 68.19% |
| 2014 Q3 | 3.23 Million USD | 120.87% |
| 2014 Q2 | 1.46 Million USD | -57.61% |
| 2014 Q1 | 3.45 Million USD | -67.28% |
| 2013 Q1 | 3.55 Million USD | -13.34% |
| 2013 Q3 | 2.38 Million USD | 190.99% |
| 2013 Q4 | 10.56 Million USD | 342.32% |
| 2013 FY | 17.33 Million USD | -34.09% |
| 2013 Q2 | 821 Thousand USD | -76.9% |
| 2012 FY | 26.29 Million USD | 33.85% |
| 2012 Q2 | 4.21 Million USD | -65.55% |
| 2012 Q3 | 5.76 Million USD | 36.84% |
| 2012 Q4 | 4.1 Million USD | -28.81% |
| 2012 Q1 | 12.22 Million USD | 133.94% |
| 2011 Q1 | 5.43 Million USD | -67.44% |
| 2011 Q2 | 3.73 Million USD | -31.28% |
| 2011 Q3 | 5.24 Million USD | 40.54% |
| 2011 Q4 | 5.22 Million USD | -0.48% |
| 2011 FY | 19.64 Million USD | -69.07% |
| 2010 Q4 | 16.69 Million USD | 39.12% |
| 2010 FY | 63.5 Million USD | -14.87% |
| 2010 Q3 | 12 Million USD | 57.56% |
| 2010 Q1 | 26.07 Million USD | -52.51% |
| 2010 Q2 | 7.61 Million USD | -70.79% |
| 2009 Q3 | 10.54 Million USD | 120.35% |
| 2009 Q1 | 4.35 Million USD | -87.27% |
| 2009 FY | 74.58 Million USD | 31.87% |
| 2009 Q4 | 54.89 Million USD | 420.43% |
| 2009 Q2 | 4.78 Million USD | 9.82% |
| 2008 FY | 56.56 Million USD | -20.6% |
| 2008 Q4 | 34.24 Million USD | 284.98% |
| 2008 Q3 | 8.89 Million USD | 234.49% |
| 2008 Q2 | 2.65 Million USD | -75.31% |
| 2008 Q1 | 10.76 Million USD | -61.78% |
| 2007 Q3 | 20.46 Million USD | 52.21% |
| 2007 Q2 | 13.44 Million USD | 46.78% |
| 2007 Q1 | 9.15 Million USD | 337.82% |
| 2007 FY | 71.23 Million USD | 1046.79% |
| 2007 Q4 | 28.17 Million USD | 37.67% |
| 2006 Q2 | 1.55 Million USD | 102.08% |
| 2006 Q1 | 771 Thousand USD | 3594.83% |
| 2006 FY | 6.21 Million USD | 3990.38% |
| 2006 Q4 | 2.09 Million USD | 16.87% |
| 2006 Q3 | 1.79 Million USD | 14.89% |
| 2005 Q4 | 20.86 Thousand USD | -34.79% |
| 2005 Q3 | 32 Thousand USD | -44.83% |
| 2005 Q2 | 58 Thousand USD | 41.46% |
| 2005 FY | 151.86 Thousand USD | -54.92% |
| 2005 Q1 | 41 Thousand USD | 112.38% |
| 2004 Q3 | 270 Thousand USD | 24.42% |
| 2004 Q2 | 217 Thousand USD | 19.89% |
| 2004 Q4 | -331.09 Thousand USD | -222.63% |
| 2004 FY | 336.9 Thousand USD | -79.38% |
| 2004 Q1 | 181 Thousand USD | -78.4% |
| 2003 Q3 | 222 Thousand USD | -16.54% |
| 2003 Q4 | 838 Thousand USD | 277.48% |
| 2003 Q2 | 266 Thousand USD | -13.64% |
| 2003 Q1 | 308 Thousand USD | -15.04% |
| 2003 FY | 1.63 Million USD | -7.92% |
| 2002 FY | 1.77 Million USD | -84.1% |
| 2002 Q4 | 362.52 Thousand USD | -12.01% |
| 2002 Q3 | 412 Thousand USD | -10.63% |
| 2002 Q2 | 461 Thousand USD | -14.47% |
| 2002 Q1 | 539 Thousand USD | -84.24% |
| 2001 Q3 | 3.4 Million USD | -6.44% |
| 2001 FY | 11.15 Million USD | 236.52% |
| 2001 Q1 | 703 Thousand USD | 151.22% |
| 2001 Q2 | 3.63 Million USD | 416.93% |
| 2001 Q4 | 3.42 Million USD | 0.61% |
| 2000 Q3 | 60 Thousand USD | -87.55% |
| 2000 FY | 3.31 Million USD | 32.62% |
| 2000 Q4 | -1.37 Million USD | -2387.34% |
| 2000 Q2 | 482 Thousand USD | -90.77% |
| 2000 Q1 | 5.22 Million USD | 0.0% |
| 1999 Q4 | - USD | -100.0% |
| 1999 FY | 2.5 Million USD | -60.94% |
| 1999 Q3 | 100 Thousand USD | -95.45% |
| 1999 Q2 | 2.2 Million USD | 1000.0% |
| 1999 Q1 | 200 Thousand USD | -50.0% |
| 1998 Q1 | 100 Thousand USD | 0.0% |
| 1998 Q4 | 400 Thousand USD | -93.33% |
| 1998 Q3 | 6 Million USD | 5900.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 FY | 6.4 Million USD | 540.0% |
| 1997 Q1 | 500 Thousand USD | 0.0% |
| 1997 FY | 1 Million USD | -62.96% |
| 1997 Q4 | - USD | -100.0% |
| 1997 Q3 | 100 Thousand USD | -92.86% |
| 1997 Q2 | 1.4 Million USD | 180.0% |
| 1996 Q2 | 1.7 Million USD | 1600.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 FY | 2.7 Million USD | 1250.0% |
| 1996 Q4 | 500 Thousand USD | 66.67% |
| 1996 Q3 | 300 Thousand USD | -82.35% |
| 1995 Q1 | 200 Thousand USD | 0.0% |
| 1995 FY | 200 Thousand USD | -71.43% |
| 1995 Q3 | 100 Thousand USD | 0.0% |
| 1995 Q4 | 100 Thousand USD | 0.0% |
| 1995 Q2 | 100 Thousand USD | -50.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 Q3 | 200 Thousand USD | 100.0% |
| 1994 Q4 | 200 Thousand USD | 0.0% |
| 1994 FY | 700 Thousand USD | 0.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Absci Corporation | 5.71 Million USD | -5695.943% |
| Adaptive Biotechnologies Corporation | 170.27 Million USD | -94.632% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 81.873% |
| Alzamend Neuro, Inc. | - USD | -Infinity% |
| Apollomics, Inc. | 821 Thousand USD | -40266.87% |
| 180 Life Sciences Corp. | - USD | -Infinity% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| Bicycle Therapeutics plc | 26.97 Million USD | -1128.544% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | -41223.192% |
| BioXcel Therapeutics, Inc. | 1.38 Million USD | -23915.362% |
| CASI Pharmaceuticals, Inc. | 33.87 Million USD | -878.222% |
| Chimerix, Inc. | 324 Thousand USD | -102187.654% |
| CRISPR Therapeutics AG | 371.2 Million USD | 10.72% |
| Contineum Therapeutics, Inc. Class A Common Stock | 50 Million USD | -562.824% |
| EyePoint Pharmaceuticals, Inc. | 46.01 Million USD | -620.179% |
| Fortress Biotech, Inc. | 84.51 Million USD | -292.143% |
| Fortress Biotech, Inc. | 84.51 Million USD | -292.143% |
| Gritstone bio, Inc. | 1.33 Million USD | -24799.474% |
| Allakos Inc. | - USD | -Infinity% |
| Boundless Bio, Inc. Common Stock | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -1480.561% |
| Cytokinetics, Incorporated | 7.53 Million USD | -4301.222% |
| enGene Holdings Inc. Common Stock | - USD | -Infinity% |
| Innoviva, Inc. | 310.46 Million USD | -6.748% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | - USD | -Infinity% |
| Salarius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Terns Pharmaceuticals, Inc. | - USD | -Infinity% |
| Vigil Neuroscience, Inc. | - USD | -Infinity% |
| ImmuCell Corporation | 17.47 Million USD | -1796.854% |
| IDEAYA Biosciences, Inc. | 23.38 Million USD | -1317.199% |
| Incyte Corporation | 3.69 Billion USD | 91.032% |
| Inovio Pharmaceuticals, Inc. | 832.01 Thousand USD | -39732.694% |
| Lexaria Bioscience Corp. | 226.2 Thousand USD | -146407.639% |
| Mustang Bio, Inc. | - USD | -Infinity% |
| MiMedx Group, Inc. | 321.47 Million USD | -3.09% |
| MEI Pharma, Inc. | 65.29 Million USD | -407.546% |
| MacroGenics, Inc. | 58.74 Million USD | -464.115% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Mereo BioPharma Group plc | 10 Million USD | -3214.12% |
| Marker Therapeutics, Inc. | 3.31 Million USD | -9909.021% |
| Marinus Pharmaceuticals, Inc. | 30.98 Million USD | -969.45% |
| Maravai LifeSciences Holdings, Inc. | 288.94 Million USD | -14.697% |
| Minerva Neurosciences, Inc. | - USD | -Infinity% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| NeuroSense Therapeutics Ltd. | - USD | -Infinity% |
| NextCure, Inc. | - USD | -Infinity% |
| Orchestra BioMed Holdings, Inc. | 2.76 Million USD | -11907.681% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | -1639.787% |
| Onconetix, Inc. | 58.46 Thousand USD | -566755.384% |
| Oncternal Therapeutics, Inc. | 785 Thousand USD | -42118.089% |
| Opthea Limited | 261.85 Thousand USD | -126461.241% |
| Ovid Therapeutics Inc. | 391.69 Thousand USD | -84509.709% |
| Psyence Biomedical Ltd. | - USD | -Infinity% |
| PDS Biotechnology Corporation | - USD | -Infinity% |
| Precigen, Inc. | 6.22 Million USD | -5223.888% |
| Pieris Pharmaceuticals, Inc. | 42.81 Million USD | -674.146% |
| Prime Medicine, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -9852.312% |
| Rocket Pharmaceuticals, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 97.473% |
| Replimune Group, Inc. | - USD | -Infinity% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Rigel Pharmaceuticals, Inc. | 116.88 Million USD | -183.544% |
| TransCode Therapeutics, Inc. | - USD | -Infinity% |
| Revolution Medicines, Inc. Warrant | 11.58 Million USD | -2761.934% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sesen Bio, Inc. | 40 Million USD | -728.53% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -88.054% |
| Solid Biosciences Inc. | - USD | -Infinity% |
| Syndax Pharmaceuticals, Inc. | - USD | -Infinity% |
| SciSparc Ltd. | 2.87 Million USD | -11411.358% |
| Sutro Biopharma, Inc. | 153.73 Million USD | -115.579% |
| TG Therapeutics, Inc. | 233.66 Million USD | -41.834% |
| Tonix Pharmaceuticals Holding Corp. | 7.76 Million USD | -4166.375% |
| Titan Pharmaceuticals, Inc. | 184 Thousand USD | -180015.217% |
| Travere Therapeutics, Inc. | 145.23 Million USD | -128.185% |
| UroGen Pharma Ltd. | 82.71 Million USD | -300.677% |
| Verrica Pharmaceuticals Inc. | 5.12 Million USD | -6367.838% |
| XOMA Corporation | 4.75 Million USD | -6865.364% |
| Zentalis Pharmaceuticals, Inc. | - USD | -Infinity% |
| AbCellera Biologics Inc. | 38.02 Million USD | -771.563% |
| Longboard Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Precision BioSciences, Inc. | 48.72 Million USD | -580.14% |
| Dyadic International, Inc. | 2.89 Million USD | -11332.707% |
| Intensity Therapeutics, Inc. | - USD | -Infinity% |
| Eton Pharmaceuticals, Inc. | 31.64 Million USD | -947.38% |
| VYNE Therapeutics Inc. | 424 Thousand USD | -78063.208% |
| Tenaya Therapeutics, Inc. | - USD | -Infinity% |
| IGM Biosciences, Inc. | 2.13 Million USD | -15459.249% |
| X4 Pharmaceuticals, Inc. | - USD | -Infinity% |
| Acelyrin, Inc. | - USD | -Infinity% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -9368.914% |
| Ligand Pharmaceuticals Incorporated | 131.31 Million USD | -152.381% |
| Inhibikase Therapeutics, Inc. | 260.5 Thousand USD | -127121.497% |
| Arcturus Therapeutics Holdings Inc. | 157.74 Million USD | -110.09% |
| Syros Pharmaceuticals, Inc. | 9.93 Million USD | -3235.467% |
| Senti Biosciences, Inc. | 2.56 Million USD | -12840.726% |
| Mesoblast Limited | 5.9 Million USD | -5515.249% |
| Kymera Therapeutics, Inc. | 78.59 Million USD | -321.687% |
| ChromaDex Corporation | 83.57 Million USD | -296.568% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Akebia Therapeutics, Inc. | 194.62 Million USD | -70.284% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Seer, Inc. | 15.18 Million USD | -2082.927% |
| Xeris Biopharma Holdings, Inc. | 163.91 Million USD | -102.187% |
| Novavax, Inc. | 983.7 Million USD | 66.31% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Fate Therapeutics, Inc. | 63.53 Million USD | -421.638% |
| Checkpoint Therapeutics, Inc. | 103 Thousand USD | -321659.223% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -254832.308% |
| Celcuity Inc. | - USD | -Infinity% |
| ContextLogic Inc. | 287 Million USD | -15.475% |
| Phathom Pharmaceuticals, Inc. | 682 Thousand USD | -48494.135% |
| HOOKIPA Pharma Inc. | 20.12 Million USD | -1546.44% |
| Jazz Pharmaceuticals plc | 3.83 Billion USD | 91.356% |
| Amarin Corporation plc | 306.91 Million USD | -7.983% |
| AnaptysBio, Inc. | 17.15 Million USD | -1831.643% |
| Aptevo Therapeutics Inc. | - USD | -Infinity% |
| Aptorum Group Limited | 431.37 Thousand USD | -76726.356% |
| Cartesian Therapeutics, Inc. | 26 Million USD | -1174.465% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | -37.667% |
| Ardelyx, Inc. | 124.45 Million USD | -166.288% |
| Celularity Inc. | 22.77 Million USD | -1355.413% |
| Omeros Corporation | - USD | -Infinity% |
| Humacyte, Inc. | - USD | -Infinity% |
| Immunocore Holdings plc | 249.42 Million USD | -32.869% |
| IO Biotech, Inc. | - USD | -Infinity% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | - USD | -Infinity% |
| Summit Therapeutics Inc. | - USD | -Infinity% |
| Alaunos Therapeutics, Inc. | 5000.00 USD | -6628140.0% |
| Pulmatrix, Inc. | 7.29 Million USD | -4441.135% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -813.61% |
| Evogene Ltd. | 5.64 Million USD | -5776.099% |
| CorMedix Inc. | - USD | -Infinity% |
| BioLineRx Ltd. | 4.8 Million USD | -6804.417% |
| VistaGen Therapeutics, Inc. | 1.06 Million USD | -31047.744% |
| Sagimet Biosciences Inc. | 2 Million USD | -16470.6% |
| PTC Therapeutics, Inc. | 937.82 Million USD | 64.662% |
| scPharmaceuticals Inc. | 13.59 Million USD | -2338.108% |
| Fulcrum Therapeutics, Inc. | 2.8 Million USD | -11715.045% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 31.296% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Akero Therapeutics, Inc. | - USD | -Infinity% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| Lisata Therapeutics, Inc. | - USD | -Infinity% |
| Stoke Therapeutics, Inc. | 8.78 Million USD | -3674.624% |
| Reneo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Outlook Therapeutics, Inc. | - USD | -Infinity% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| Daré Bioscience, Inc. | 2.8 Million USD | -11702.905% |
| bluebird bio, Inc. | 29.49 Million USD | -1023.545% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 86.301% |
| DBV Technologies S.A. | 15.72 Million USD | -2007.146% |
| Avidity Biosciences, Inc. | 9.56 Million USD | -3366.653% |
| Galecto, Inc. | - USD | -Infinity% |
| Sensei Biotherapeutics, Inc. | - USD | -Infinity% |
| Spruce Biosciences, Inc. | 10.08 Million USD | -3184.885% |
| Inhibrx Biosciences, Inc. | 1.8 Million USD | -18311.778% |
| GlycoMimetics, Inc. | 10 Thousand USD | -3314020.0% |
| Arcutis Biotherapeutics, Inc. | 59.6 Million USD | -456.004% |
| ADMA Biologics, Inc. | 258.21 Million USD | -28.347% |
| Clene Inc. | 654 Thousand USD | -50574.618% |
| Recursion Pharmaceuticals, Inc. | 44.57 Million USD | -643.493% |
| Aptose Biosciences Inc. | - USD | -Infinity% |
| ZyVersa Therapeutics, Inc. | - USD | -Infinity% |
| Soligenix, Inc. | 839.35 Thousand USD | -39383.94% |
| Century Therapeutics, Inc. | 2.23 Million USD | -14728.277% |
| Kura Oncology, Inc. | - USD | -Infinity% |
| Surrozen, Inc. | - USD | -Infinity% |
| TScan Therapeutics, Inc. | 21.04 Million USD | -1474.479% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 101.21 Million USD | -227.437% |
| Autolus Therapeutics plc | 1.69 Million USD | -19417.786% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| Eterna Therapeutics Inc. | 68 Thousand USD | -487270.588% |
| Caribou Biosciences, Inc. | 34.47 Million USD | -861.255% |
| GRI Bio, Inc. | 21.76 Million USD | -1422.543% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | -12947.788% |
| Janux Therapeutics, Inc. | 8.08 Million USD | -4000.111% |
| INmune Bio, Inc. | 155 Thousand USD | -213714.194% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -160.864% |
| SAB Biotherapeutics, Inc. | 2.23 Million USD | -14701.846% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Tenax Therapeutics, Inc. | - USD | -Infinity% |
| Jaguar Health, Inc. | 9.76 Million USD | -3295.267% |
| Entero Therapeutics, Inc. | - USD | -Infinity% |
| Milestone Pharmaceuticals Inc. | 1 Million USD | -33041.2% |
| Clearside Biomedical, Inc. | 8.22 Million USD | -3928.835% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -3765.765% |
| Coherus BioSciences, Inc. | 257.24 Million USD | -28.832% |
| Verastem, Inc. | - USD | -Infinity% |
| Pliant Therapeutics, Inc. | 1.58 Million USD | -20875.443% |
| Histogen Inc. | 3.76 Million USD | -8693.102% |
| Aprea Therapeutics, Inc. | 583.23 Thousand USD | -56723.454% |
| ACADIA Pharmaceuticals Inc. | 726.43 Million USD | 54.378% |
| Surrozen, Inc. | - USD | -Infinity% |
| Organovo Holdings, Inc. | 109 Thousand USD | -303947.706% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Cadrenal Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Centessa Pharmaceuticals plc | 6.85 Million USD | -4736.013% |
| Hepion Pharmaceuticals, Inc. | - USD | -Infinity% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -227205.898% |
| Kronos Bio, Inc. | 6.28 Million USD | -5170.547% |
| Turnstone Biologics Corp. | 19.3 Million USD | -1616.627% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | - USD | -Infinity% |
| Entrada Therapeutics, Inc. | 129.01 Million USD | -156.883% |
| Aurinia Pharmaceuticals Inc. | 175.51 Million USD | -88.825% |
| Exelixis, Inc. | 1.83 Billion USD | 81.892% |
| Nurix Therapeutics, Inc. | 76.98 Million USD | -330.478% |
| Apellis Pharmaceuticals, Inc. | 396.59 Million USD | 16.435% |
| Jasper Therapeutics, Inc. | - USD | -Infinity% |
| ESSA Pharma Inc. | - USD | -Infinity% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 139.91 Million USD | -136.873% |
| Insmed Incorporated | 305.2 Million USD | -8.586% |
| MediWound Ltd. | 18.68 Million USD | -1673.585% |
| OmniAb, Inc. | 34.16 Million USD | -870.062% |
| Alector, Inc. | 97.06 Million USD | -241.444% |
| Seres Therapeutics, Inc. | 126.32 Million USD | -162.349% |
| Zai Lab Limited | 266.71 Million USD | -24.255% |
| AlloVir, Inc. | - USD | -Infinity% |
| Revance Therapeutics, Inc. | 234.04 Million USD | -41.605% |
| ORIC Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aura Biosciences, Inc. | - USD | -Infinity% |
| Immunic, Inc. | - USD | -Infinity% |
| Tarsus Pharmaceuticals, Inc. | 17.44 Million USD | -1799.536% |
| Veracyte, Inc. | 361.05 Million USD | 8.209% |
| InMed Pharmaceuticals Inc. | 4.59 Million USD | -7108.166% |
| FibroGen, Inc. | 147.75 Million USD | -124.303% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| Catalyst Pharmaceuticals, Inc. | 398.2 Million USD | 16.773% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 147.8 Thousand USD | -224122.455% |
| Cyclacel Pharmaceuticals, Inc. | 420 Thousand USD | -78807.619% |
| Amylyx Pharmaceuticals, Inc. | 380.78 Million USD | 12.966% |
| Fortrea Holdings Inc. | 3.1 Billion USD | 89.34% |
| KalVista Pharmaceuticals, Inc. | - USD | -Infinity% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | - USD | -Infinity% |
| Keros Therapeutics, Inc. | 151 Thousand USD | -219378.146% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Lyra Therapeutics, Inc. | 1.55 Million USD | -21171.63% |
| Foghorn Therapeutics Inc. | 34.15 Million USD | -870.318% |
| Agenus Inc. | 156.31 Million USD | -112.017% |
| Y-mAbs Therapeutics, Inc. | 84.81 Million USD | -290.728% |
| Theravance Biopharma, Inc. | 57.42 Million USD | -477.132% |
| Ultragenyx Pharmaceutical Inc. | 434.24 Million USD | 23.682% |
| Metagenomi, Inc. Common Stock | 44.75 Million USD | -640.486% |
| Gain Therapeutics, Inc. | 55.18 Thousand USD | -600501.667% |
| C4 Therapeutics, Inc. | 20.75 Million USD | -1496.705% |
| Creative Medical Technology Holdings, Inc. | 9000.00 USD | -3682255.556% |
| Chemomab Therapeutics Ltd. | - USD | -Infinity% |
| Lantern Pharma Inc. | - USD | -Infinity% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ainos, Inc. | 122.11 Thousand USD | -271300.026% |
| Pluri Inc. | 326 Thousand USD | -101560.123% |
| Prothena Corporation plc | 91.37 Million USD | -262.714% |
| Adaptimmune Therapeutics plc | 60.28 Million USD | -449.779% |
| Rallybio Corporation | - USD | -Infinity% |
| Kodiak Sciences Inc. | - USD | -Infinity% |
| Cue Biopharma, Inc. | 5.49 Million USD | -5936.648% |
| MeiraGTx Holdings plc | 14.01 Million USD | -2264.358% |
| Annexon, Inc. | - USD | -Infinity% |
| Assembly Biosciences, Inc. | 7.16 Million USD | -4526.721% |
| Moderna, Inc. | 6.84 Billion USD | 95.16% |
| Cocrystal Pharma, Inc. | - USD | -Infinity% |
| Cidara Therapeutics, Inc. | 63.9 Million USD | -418.601% |
| Blueprint Medicines Corporation | 249.38 Million USD | -32.894% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Monte Rosa Therapeutics, Inc. | - USD | -Infinity% |
| Scholar Rock Holding Corporation | - USD | -Infinity% |
| Wave Life Sciences Ltd. | 113.3 Million USD | -192.495% |
| Sana Biotechnology, Inc. | - USD | -Infinity% |
| Elicio Therapeutics, Inc. | - USD | -Infinity% |
| Adlai Nortye Ltd. American Depositary Shares | 4.99 Million USD | -6534.008% |
| Nutriband Inc. | 2.08 Million USD | -15792.667% |
| Protara Therapeutics, Inc. | - USD | -Infinity% |
| Vor Biopharma Inc. | - USD | -Infinity% |
| Roivant Sciences Ltd. | 124.79 Million USD | -165.565% |
| Alkermes plc | 1.66 Billion USD | 80.076% |
| ProKidney Corp. | - USD | -Infinity% |
| Applied Therapeutics, Inc. | 9.99 Million USD | -3216.442% |
| Arcellx, Inc. | 110.31 Million USD | -200.412% |
| BridgeBio Pharma, Inc. | 9.3 Million USD | -3462.421% |
| Tango Therapeutics, Inc. | 36.52 Million USD | -807.307% |
| Galectin Therapeutics Inc. | - USD | -Infinity% |
| Atai Life Sciences N.V. | 314 Thousand USD | -105445.223% |
| Renovaro Biosciences Inc. | - USD | -Infinity% |
| Aerovate Therapeutics, Inc. | - USD | -Infinity% |
| MediciNova, Inc. | 1 Million USD | -33041.2% |
| Praxis Precision Medicines, Inc. | 2.44 Million USD | -13443.604% |
| Cardio Diagnostics Holdings, Inc. | 17.06 Thousand USD | -1941956.841% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -22.473% |
| Biomea Fusion, Inc. | - USD | -Infinity% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Cullinan Oncology, Inc. | - USD | -Infinity% |
| Geron Corporation | 237 Thousand USD | -139736.287% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| 4D Molecular Therapeutics, Inc. | 20.72 Million USD | -1499.247% |
| Dyne Therapeutics, Inc. | - USD | -Infinity% |
| Kiniksa Pharmaceuticals, Ltd. | 270.25 Million USD | -22.628% |
| Royalty Pharma plc | 2.35 Billion USD | 85.925% |
| Ventyx Biosciences, Inc. | - USD | -Infinity% |
| Imunon, Inc. | - USD | -Infinity% |
| BioAtla, Inc. | - USD | -Infinity% |
| Allogene Therapeutics, Inc. | 95 Thousand USD | -348754.737% |
| Larimar Therapeutics, Inc. | - USD | -Infinity% |
| Mersana Therapeutics, Inc. | 36.85 Million USD | -799.232% |
| Structure Therapeutics Inc. | - USD | -Infinity% |
| 89bio, Inc. | - USD | -Infinity% |
| Kezar Life Sciences, Inc. | 7 Million USD | -4634.457% |
| aTyr Pharma, Inc. | 353 Thousand USD | -93784.419% |
| Aligos Therapeutics, Inc. | 15.52 Million USD | -2034.149% |
| Viridian Therapeutics, Inc. | 314 Thousand USD | -105445.223% |
| EyeGate Pharmaceuticals, Inc. | 12.05 Thousand USD | -2748154.416% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 60.035% |
| Lexicon Pharmaceuticals, Inc. | 1.2 Million USD | -27425.914% |
| Liquidia Corporation | 17.48 Million USD | -1795.082% |
| Entera Bio Ltd. | - USD | -Infinity% |
| GH Research PLC | - USD | -Infinity% |
| Vericel Corporation | 197.51 Million USD | -67.79% |
| Arbutus Biopharma Corporation | 18.14 Million USD | -1726.867% |
| Xencor, Inc. | 168.33 Million USD | -96.873% |
| 60 Degrees Pharmaceuticals, Inc. | 253.57 Thousand USD | -130596.88% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Coeptis Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Vaxcyte, Inc. | - USD | -Infinity% |
| Xenon Pharmaceuticals Inc. | - USD | -Infinity% |
| Vanda Pharmaceuticals Inc. | 192.64 Million USD | -72.037% |
| Lexaria Bioscience Corp. | 226.2 Thousand USD | -146407.639% |
| Portage Biotech Inc. | - USD | -Infinity% |
| Cardio Diagnostics Holdings, Inc. | 17.06 Thousand USD | -1941956.841% |
| Olema Pharmaceuticals, Inc. | - USD | -Infinity% |
| OncoCyte Corporation | 1.5 Million USD | -21950.033% |
| Qualigen Therapeutics, Inc. | 5.2 Million USD | -6267.485% |
| Processa Pharmaceuticals, Inc. | - USD | -Infinity% |
| Purple Biotech Ltd. | - USD | -Infinity% |
| Tempest Therapeutics, Inc. | - USD | -Infinity% |
| Sol-Gel Technologies Ltd. | 1.55 Million USD | -21226.384% |
| Rhythm Pharmaceuticals, Inc. | 77.42 Million USD | -328.026% |
| CollPlant Biotechnologies Ltd. | 10.95 Million USD | -2924.108% |
| Moleculin Biotech, Inc. | - USD | -Infinity% |
| United Therapeutics Corporation | 2.32 Billion USD | 85.761% |
| HilleVax, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 72.1 Thousand USD | -459543.283% |
| Telomir Pharmaceuticals, Inc. Common Stock | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | -35.096% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Pyxis Oncology, Inc. | - USD | -Infinity% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| Curis, Inc. | 10.02 Million USD | -3206.515% |
| Carmell Therapeutics Corporation | - USD | -Infinity% |
| Achieve Life Sciences, Inc. | - USD | -Infinity% |
| BeiGene, Ltd. | 2.45 Billion USD | 86.521% |
| Protagonist Therapeutics, Inc. | 60 Million USD | -452.353% |
| Erasca, Inc. | - USD | -Infinity% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | - USD | -Infinity% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | -4039.545% |
| Acrivon Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Celldex Therapeutics, Inc. | 6.88 Million USD | -4714.935% |
| Cogent Biosciences, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 17.013% |
| Aditxt, Inc. | 645.17 Thousand USD | -51267.689% |
| Adagene Inc. | 18.11 Million USD | -1729.844% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 1.08 Million USD | -30529.575% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 250 Million USD | -32.561% |
| Compugen Ltd. | 33.45 Million USD | -890.502% |
| Generation Bio Co. | 5.9 Million USD | -5513.347% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | - USD | -Infinity% |
| Invivyd, Inc. | - USD | -Infinity% |
| Relay Therapeutics, Inc. | 25.54 Million USD | -1197.315% |
| Quoin Pharmaceuticals, Ltd. | - USD | -Infinity% |
| Spero Therapeutics, Inc. | 96.73 Million USD | -242.598% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 100.38 Million USD | -230.134% |
| Instil Bio, Inc. | - USD | -Infinity% |
| Capricor Therapeutics, Inc. | 25.17 Million USD | -1216.273% |
| Elevai Labs, Inc. Common Stock | 1.71 Million USD | -19251.452% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Citius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| ALX Oncology Holdings Inc. | - USD | -Infinity% |
| Vir Biotechnology, Inc. | 86.18 Million USD | -284.558% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -453193.577% |
| Ocular Therapeutix, Inc. | 58.44 Million USD | -467.069% |
| Verve Therapeutics, Inc. | 11.75 Million USD | -2718.609% |
| Tyra Biosciences, Inc. | - USD | -Infinity% |
| Cingulate Inc. | - USD | -Infinity% |
| Galmed Pharmaceuticals Ltd. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Connect Biopharma Holdings Limited | - USD | -Infinity% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Bolt Biotherapeutics, Inc. | 7.87 Million USD | -4107.872% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Madrigal Pharmaceuticals, Inc. | - USD | -Infinity% |
| ImmunityBio, Inc. | 622 Thousand USD | -53181.672% |
| Korro Bio, Inc. | - USD | -Infinity% |
| Kineta, Inc. | 5.44 Million USD | -5989.893% |
| BioVie Inc. | - USD | -Infinity% |
| Codexis, Inc. | 70.14 Million USD | -372.481% |
| Celularity Inc. | 22.77 Million USD | -1355.413% |
| Aileron Therapeutics, Inc. | - USD | -Infinity% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | -8158.46% |
| Virax Biolabs Group Limited | 156.41 Thousand USD | -211774.517% |
| Cibus, Inc. | 1.81 Million USD | -18139.516% |
| IN8bio, Inc. | - USD | -Infinity% |
| Adverum Biotechnologies, Inc. | 3.6 Million USD | -9105.889% |
| Avalo Therapeutics, Inc. | 1.92 Million USD | -17125.156% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 57.924% |
| Eyenovia, Inc. | 3787.00 USD | -8751207.103% |
| Puma Biotechnology, Inc. | 235.63 Million USD | -40.645% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Elevation Oncology, Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | - USD | -Infinity% |
| Cardiff Oncology, Inc. | 488 Thousand USD | -67812.295% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | -318.428% |
| Regulus Therapeutics Inc. | - USD | -Infinity% |
| Moolec Science SA | 905.04 Thousand USD | -36518.128% |
| Acumen Pharmaceuticals, Inc. | - USD | -Infinity% |
| LAVA Therapeutics N.V. | 6.76 Million USD | -4796.026% |
| Atea Pharmaceuticals, Inc. | - USD | -Infinity% |
| Compass Therapeutics, Inc. | - USD | -Infinity% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 733.87 Thousand USD | -45059.435% |
| Humacyte, Inc. | - USD | -Infinity% |
| PMV Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 170 Thousand USD | -194848.235% |
| Trevi Therapeutics, Inc. | - USD | -Infinity% |
| Notable Labs, Ltd. | 310 Thousand USD | -106807.097% |
| Immunovant, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 1.08 Million USD | -30529.575% |
| DiaMedica Therapeutics Inc. | - USD | -Infinity% |
| Vera Therapeutics, Inc. | 1.86 Million USD | -17698.711% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Soleno Therapeutics, Inc. | - USD | -Infinity% |
| PepGen Inc. | - USD | -Infinity% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | - USD | -Infinity% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Belite Bio, Inc | - USD | -Infinity% |
| XOMA Corporation | 4.75 Million USD | -6865.364% |
| ARS Pharmaceuticals, Inc. | 30 Thousand USD | -1104606.667% |
| Bionomics Limited | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -1991.851% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 64.7 Million USD | -412.205% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | - USD | -Infinity% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | - USD | -Infinity% |
| Altimmune, Inc. | 426 Thousand USD | -77696.244% |
| LENZ Therapeutics, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | - USD | -Infinity% |
| Peak Bio, Inc. | 367.87 Thousand USD | -89987.72% |
| Zevra Therapeutics, Inc. | 27.46 Million USD | -1106.846% |
| Benitec Biopharma Inc. | 216 Thousand USD | -153331.481% |
| Spyre Therapeutics, Inc. | 886 Thousand USD | -37305.418% |
| NKGen Biotech, Inc. Common Stock | - USD | -Infinity% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | - USD | -Infinity% |
| NKGen Biotech, Inc. Warrants | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 72.975% |
| Immunome, Inc. | 14.01 Million USD | -2264.189% |
| Verona Pharma plc | - USD | -Infinity% |
| enGene Holdings Inc. Warrants | - USD | -Infinity% |
| Shattuck Labs, Inc. | 1.65 Million USD | -19900.724% |
| CervoMed Inc. | 7.14 Million USD | -4538.46% |
| Plus Therapeutics, Inc. | 4.91 Million USD | -6645.614% |
| Dianthus Therapeutics, Inc. | 2.82 Million USD | -11627.247% |
| Moolec Science SA | 905.04 Thousand USD | -36518.128% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Design Therapeutics, Inc. | - USD | -Infinity% |
| Leap Therapeutics, Inc. | - USD | -Infinity% |
| Seelos Therapeutics, Inc. | 2.2 Million USD | -14943.668% |
| Achilles Therapeutics plc | - USD | -Infinity% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| CG Oncology, Inc. Common stock | 204 Thousand USD | -162356.863% |
| Fractyl Health, Inc. Common Stock | 120 Thousand USD | -276076.667% |
| Rani Therapeutics Holdings, Inc. | - USD | -Infinity% |
| MoonLake Immunotherapeutics | - USD | -Infinity% |
| Tourmaline Bio, Inc. | - USD | -Infinity% |
| Beam Therapeutics Inc. | 377.7 Million USD | 12.257% |
| Mirum Pharmaceuticals, Inc. | 186.37 Million USD | -77.821% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| Aadi Bioscience, Inc. | 24.35 Million USD | -1260.811% |
| Enliven Therapeutics, Inc. | - USD | -Infinity% |
| Kiora Pharmaceuticals, Inc. | - USD | -Infinity% |
| NeurAxis, Inc. | 2.46 Million USD | -13371.764% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -27773.171% |
| Lumos Pharma, Inc. | 2.05 Million USD | -16058.557% |
| Opiant Pharmaceuticals, Inc. | 40.72 Million USD | -713.777% |
| Palisade Bio, Inc. | 250 Thousand USD | -132464.8% |
| Nutriband Inc. | 2.08 Million USD | -15792.667% |
| Taysha Gene Therapies, Inc. | 15.45 Million USD | -2044.923% |
| Neurogene Inc. | - USD | -Infinity% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Athira Pharma, Inc. | - USD | -Infinity% |
| HCW Biologics Inc. | 2.84 Million USD | -11562.07% |
| XOMA Corporation | 4.75 Million USD | -6865.364% |
| Nektar Therapeutics | 90.12 Million USD | -267.737% |
| Arvinas, Inc. | 78.5 Million USD | -322.181% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Merus N.V. | 43.94 Million USD | -654.117% |
| Omega Therapeutics, Inc. | 3.09 Million USD | -10611.441% |
| Quince Therapeutics, Inc. | - USD | -Infinity% |
| Rezolute, Inc. | - USD | -Infinity% |
| Clene Inc. | 654 Thousand USD | -50574.618% |
| Indaptus Therapeutics, Inc. | - USD | -Infinity% |
| BeyondSpring Inc. | 1.75 Million USD | -18827.013% |
| Synlogic, Inc. | 3.37 Million USD | -9731.267% |
| Allarity Therapeutics, Inc. | - USD | -Infinity% |
| Phio Pharmaceuticals Corp. | - USD | -Infinity% |
| Peak Bio, Inc. | 367.87 Thousand USD | -89987.72% |
| Werewolf Therapeutics, Inc. | 19.94 Million USD | -1561.796% |
| Krystal Biotech, Inc. | 50.69 Million USD | -553.685% |
| Karyopharm Therapeutics Inc. | 146.03 Million USD | -126.943% |
| SpringWorks Therapeutics, Inc. | 5.44 Million USD | -5984.303% |
| Lipella Pharmaceuticals Inc. | 449.61 Thousand USD | -73609.846% |
| MannKind Corporation | 198.96 Million USD | -66.571% |
| Ikena Oncology, Inc. | 9.16 Million USD | -3518.035% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 113.45 Million USD | -192.122% |
| Gossamer Bio, Inc. | - USD | -Infinity% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | - USD | -Infinity% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Legend Biotech Corporation | 285.14 Million USD | -16.227% |
| Mural Oncology plc | - USD | -Infinity% |
| Disc Medicine, Inc. | - USD | -Infinity% |
| Champions Oncology, Inc. | 50.15 Million USD | -560.776% |
| REGENXBIO Inc. | 90.24 Million USD | -267.248% |
| Ensysce Biosciences, Inc. | 2.23 Million USD | -14758.06% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | - USD | -Infinity% |
| Edgewise Therapeutics, Inc. | - USD | -Infinity% |
| Vaxart, Inc. | 7.37 Million USD | -4391.286% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | - USD | -Infinity% |
| Cellectis S.A. | 755 Thousand USD | -43795.629% |
| Longeveron Inc. | 709 Thousand USD | -46643.583% |
| Repare Therapeutics Inc. | 51.13 Million USD | -548.137% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 73.345% |
| Inozyme Pharma, Inc. | - USD | -Infinity% |
| Revolution Medicines, Inc. | 11.58 Million USD | -2761.934% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | - USD | -Infinity% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 210 Thousand USD | -157715.238% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 96.642% |
| Denali Therapeutics Inc. | 330.53 Million USD | -0.267% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 16.29 Million USD | -1933.582% |
| Corvus Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cingulate Inc. | - USD | -Infinity% |
| Passage Bio, Inc. | - USD | -Infinity% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | - USD | -Infinity% |
| Day One Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | -12160.895% |
| Scinai Immunotherapeutics Ltd. | - USD | -Infinity% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 152.43 Thousand USD | -217319.143% |
| Carisma Therapeutics, Inc. | 14.91 Million USD | -2121.409% |
| Unicycive Therapeutics, Inc. | 675 Thousand USD | -48998.074% |
| OmniAb, Inc. | 34.16 Million USD | -870.062% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 21.25 Million USD | -1459.439% |
| Lipocine Inc. | -2.85 Million USD | 11725.155% |
| Lexeo Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Nautilus Biotechnology, Inc. | - USD | -Infinity% |
| SAB Biotherapeutics, Inc. | 2.23 Million USD | -14701.846% |
| G1 Therapeutics, Inc. | 82.51 Million USD | -301.658% |
| Bellerophon Therapeutics, Inc. | - USD | -Infinity% |
| Sage Therapeutics, Inc. | 86.45 Million USD | -283.335% |
| Ocugen, Inc. | 6.03 Million USD | -5390.59% |
| Mind Medicine (MindMed) Inc. | - USD | -Infinity% |
| Q32 Bio Inc. | 1.15 Million USD | -28568.858% |
| Brainstorm Cell Therapeutics Inc. | - USD | -Infinity% |
| Alumis Inc. Common Stock | - USD | -Infinity% |
| Equillium, Inc. | 36.08 Million USD | -818.446% |
| Kyverna Therapeutics, Inc. | - USD | -Infinity% |
| Coya Therapeutics, Inc. | 6 Million USD | -5421.503% |
| CNS Pharmaceuticals, Inc. | - USD | -Infinity% |
| Dominari Holdings Inc. | 2.03 Million USD | -16153.654% |
| Edesa Biotech, Inc. | - USD | -Infinity% |
| vTv Therapeutics Inc. | - USD | -Infinity% |
| Bio-Techne Corporation | 1.15 Billion USD | 71.407% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -1135.552% |
| Harmony Biosciences Holdings, Inc. | 582.02 Million USD | 43.059% |
| Prelude Therapeutics Incorporated | - USD | -Infinity% |
| Candel Therapeutics, Inc. | - USD | -Infinity% |
| iTeos Therapeutics, Inc. | 12.59 Million USD | -2531.298% |
| Nkarta, Inc. | - USD | -Infinity% |
| BioCardia, Inc. | 477 Thousand USD | -69378.407% |
| Iterum Therapeutics plc | - USD | -Infinity% |